Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

Part of paid clinical trials in Tucson, Arizona.

Sponsor
AbbVie
Study ID
NCT00788684
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • rituximab — DRUG
    IV infusion once weekly for four doses
  • ABT-263 — DRUG
    ABT-263: oral solution or tablets, once daily dosing until disease progression

Study Details

This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with rituximab in participants with CD20-positive lymphoproliferative disorders. The extension portion of the study will allow active participants to continue to receive ABT-263 for up to 14 years after the last participant transitions with quarterly study evaluations.

Key Dates

Start date
Jul 21, 2009
Status verified
Feb 2025
Primary completion
Feb 7, 2025
Completion
Feb 7, 2025

Study Design

Enrollment
29 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: ABT-263 + rituximab

Primary Outcome Measure

Extension Study: Continued assessment of the safety profile of ABT-263 when administered in combination with rituximab [ Time Frame: Safety will be assessed until the participant discontinues the extension portion of the study. ]

Locations (4)

FacilityCityStateZIPSite coordinators
University of Arizona Cancer Center - North Campus /ID# 16721TucsonArizona85719-1478-
Stanford University School of Med /ID# 9782StanfordCalifornia94305-2200-
Cleveland Clinic Main Campus /ID# 9784ClevelandOhio44195-
Univ of Wisconsin Hosp/Clinics /ID# 21701MadisonWisconsin53792-0001-

Find similar trials in Tucson, AZ

By research site
University of Arizona Cancer Center - North Campus· Tucson, AZStanford University School of Med· Stanford, CACleveland Clinic Main Campus· Cleveland, OHUniv of Wisconsin Hosp/Clinics· Madison, WI

Related Studies